A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A Strains

Trial Profile

A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A Strains

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs MEDI 8852 (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 10 Apr 2017 Last checked against ClinicalTrials.gov record.
    • 06 Apr 2017 This trial has been discontinued in Denmark (End date:2017-03-02) as per European Clinical Trials Database record.
    • 05 Apr 2017 Planned End Date changed from 1 May 2019 to 26 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top